Upidosin

Upidosin (Rec 15/2739) is an α-1 adrenoceptor (α-1 AR) antagonist. Upidosin shows moderate selectivity for the α-1A AR subtype. Upidosin shows uroselectivity in urethra and prostate with a K_b value of 2-3 nM higher than in ear artery and aorta with a K_b value of 20-100 nM. Upidosin inhibits [3H]prazosin binding to cloned human α-1A adrenergic receptor. Upidosin can be used for the research of urethral obstruction^[1]. In Vitro:Upidosin is one of the most potent compounds action on the prostate with comparing the apparent pKB values, but its potency is slightly lower than that of tamsulosin and is higher than the potencies of prazosin, terazosin and 5-methylurapidil^[2].
Upidosin shows binding affinities to cloned human_α1A, human_α1B, human_α1D adrenoceptors with pK_i value of 9.0, 7.5 and 8.6, respectively^[3]. In Vivo:Upidosin shows greater selectivity than any other α-1 AR antagonist terazosin and tamsulosin in the anesthetized dog^[1].
Upidosin (1-300 μg/kg; i.v.) is a more potent antagonist of phenylephrine mediated increases in prostatic pressure with a pA₂ value of 8.74 compared to blood pressure with a pA₂ value of 7.51^[3].